Clinical, humanistic, and economic burden of severe haemophilia B in adults receiving factor IX prophylaxis: findings from the CHESS II real-world burden of illness study in Europe

Real-world studies of the burden of severe haemophilia B in the context of recent therapeutic advances such as extended half-life (EHL) factor IX (FIX) products are limited. We analysed data from the recent CH...

Source: Orphanet Journal of Rare Diseases - December 20, 2021 Category: Internal Medicine Authors: Tom Burke, Sohaib Asghar, Jamie O ’Hara, Margaret Chuang, Eileen K. Sawyer and Nanxin Li Tags: Research Source Type: research